Puma Biotechnology (NASDAQ:PBYI) Announces Earnings Results

Puma Biotechnology (NASDAQ:PBYI) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.02, Zacks reports. Puma Biotechnology had a return on equity of 36.17% and a net margin of 17.45%.The business had revenue of $75.50 million during the quarter, compared to analysts’ expectations of $68.60 million.

Here are the key takeaways from Puma Biotechnology’s conference call:

• Q4 2025 results showed continued commercial momentum with total revenue of $75.5M and product net revenue of $59.9M, and management guides full‑year 2026 net NERLYNX product revenue of $194M–$198M and GAAP net income of $10M–$13M.
• Management expects higher gross‑to‑net reductions (FY2026 ~27.5%–28.5%; Q1 ~29.5%–30.5%) and is guiding a Q1 2026 net loss of $8M–$10M, which could pressure near‑term margins and results.
• Clinical programs advanced — the ALISCA‑Breast1 trial reached and exceeded its 150‑patient target ahead of schedule (164 enrolled) with interim data expected in Q2 2026, and ALISCA‑Lung1 is escalating doses (60mg, planned 70mg) with an interim readout also expected in Q2 2026, representing potential near‑term catalysts.
• Commercial demand trends were healthy with ex‑factory bottle sales up ~12% q/q to 3,298 bottles, SD (specialty distributor) channel growth strong (SD +17% q/q, +46% y/y), and recent international launches (Algeria, Thailand) expanding reach.
• Puma expects R&D to rise ~30%–35% and SG&A to rise 3%–5% in 2026; cash and securities were ~$97.5M at year‑end with outstanding debt ≈$22M, so higher spend could strain liquidity if commercial trends weaken.

Puma Biotechnology Stock Down 25.9%

Shares of PBYI traded down $1.97 during trading hours on Friday, reaching $5.64. The stock had a trading volume of 1,237,290 shares, compared to its average volume of 434,942. Puma Biotechnology has a 52 week low of $2.58 and a 52 week high of $7.68. The firm has a 50-day moving average of $6.49 and a 200 day moving average of $5.58. The company has a market cap of $283.95 million, a P/E ratio of 7.61 and a beta of 1.22.

Analyst Upgrades and Downgrades

PBYI has been the topic of several recent analyst reports. Wall Street Zen downgraded shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Saturday, November 8th. Weiss Ratings restated a “hold (c+)” rating on shares of Puma Biotechnology in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat, Puma Biotechnology has an average rating of “Moderate Buy” and a consensus target price of $7.00.

Key Headlines Impacting Puma Biotechnology

Here are the key news stories impacting Puma Biotechnology this week:

• Positive Sentiment: Q4 results beat expectations — Puma reported Q4 revenue of $75.5M and GAAP EPS that topped consensus (reports show $0.26–$0.29 vs. estimates near $0.24), demonstrating solid topline execution and profitability metrics. Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates
• Positive Sentiment: Product revenue outlook for NERLYNX is meaningful — management provided a standalone 2026 NERLYNX revenue target in the ~$194M–$198M range and reiterated clinical progress on alisertib programs, supporting medium-term revenue visibility and pipeline optionality. Puma anticipates $194M–$198M NERLYNX revenue for 2026 while advancing alisertib clinical programs
• Neutral Sentiment: Full earnings materials and transcripts posted — the company issued its 4Q/2025 press release, slide deck and held the conference call; transcripts and call highlights are available for detailed read-through of management’s commentary. These give investors the ability to dig into margin drivers and sales cadence but don’t change facts. Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results Puma Biotech (PBYI) Earnings Call Transcript
• Negative Sentiment: Near-term revenue guidance missed street expectations — Puma guided Q1 2026 revenue to roughly $38M–$42M (consensus ~$48.6M) and FY‑2026 revenue to $214M–$221M (consensus ~$226.3M), which likely triggered the selloff despite the quarter’s beat. Puma Biotechnology Inc (PBYI) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic …
• Negative Sentiment: Limited forward EPS clarity — public materials and the release emphasized revenue ranges but did not provide firm EPS guidance, increasing near‑term uncertainty for earnings models and potentially amplifying downside risk. Puma Biotechnology, Inc. (PBYI) Q4 2025 Earnings Call Transcript

Insider Buying and Selling

In other Puma Biotechnology news, insider Douglas M. Hunt sold 5,014 shares of Puma Biotechnology stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $5.88, for a total value of $29,482.32. Following the transaction, the insider owned 155,907 shares of the company’s stock, valued at approximately $916,733.16. The trade was a 3.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Alan H. Auerbach sold 18,012 shares of the firm’s stock in a transaction on Wednesday, January 7th. The stock was sold at an average price of $5.88, for a total transaction of $105,910.56. Following the sale, the chief executive officer owned 7,145,951 shares in the company, valued at approximately $42,018,191.88. The trade was a 0.25% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 43,937 shares of company stock valued at $257,513. 23.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Puma Biotechnology

Hedge funds and other institutional investors have recently bought and sold shares of the company. Invesco Ltd. increased its stake in Puma Biotechnology by 69.7% in the 4th quarter. Invesco Ltd. now owns 108,301 shares of the biopharmaceutical company’s stock valued at $644,000 after buying an additional 44,484 shares during the last quarter. Empowered Funds LLC grew its holdings in shares of Puma Biotechnology by 55.7% in the 4th quarter. Empowered Funds LLC now owns 186,185 shares of the biopharmaceutical company’s stock valued at $1,108,000 after acquiring an additional 66,624 shares in the last quarter. Stokes Family Office LLC acquired a new stake in shares of Puma Biotechnology in the fourth quarter valued at about $167,000. Verdad Advisers LP bought a new stake in Puma Biotechnology during the fourth quarter worth about $330,000. Finally, Man Group plc acquired a new position in Puma Biotechnology during the fourth quarter valued at approximately $282,000. Institutional investors and hedge funds own 61.29% of the company’s stock.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.